Previous 10 | Next 10 |
BEDMINSTER, N.J., July 25, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has designated MAT2203, Matinas’ proprietary oral amphotericin B pr...
Baxter International (NYSE: BAX ) initiated with Sector Weight rating at KeyBanc. More news on: Baxter International Inc., Kadmon Holdings, Inc., Matinas BioPharma Holdings, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
"Americans will put up with anything provided it doesn't block traffic. ” ― Dan Rather Today, we look at a small ' Tier 4 ' biopharma concern that has had a volatile ride in its five years as a public company. Company Overview: Matinas BioPharma ( MTNB ) IPO’d...
BEDMINSTER, N.J., June 03, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer , has been invited to present at the 9 th Annual LD Micro Invitationa...
– Efficacy of oral delivery of amphotericin B (MAT2203) demonstrated comparable efficacy to IV amphotericin, with similar survival of animals and reduction in fungal burden – – Cryptococcal meningitis is one of the most frequent and opportunistic infections in Hum...
BEDMINSTER, N.J., May 21, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that its abstract of preclinical data of MAT2501, an orally administered, lipid nano-crystal (“LNC”) formulati...
Sydney, Australia (ABN Newswire) - In this segment of The Ellis Martin Report, Ellis speaks with Jerome Jabbour, the CEO of Matinas Biopharma (NYSE:MTNB). The company announced a research collaboration with ViiV Healthcare to evaluate formulation of antiviral drug candidates. Additionally, Mr...
Matinas BioPharma ( MTNB -0.3% ) inks a research collaboration agreement with ViiV Healthcare under which the latter will explore the use of the former's lipid nano-crystal (LNC) platform delivery technology in developing new antivirals. More news on: Matinas BioPharma Holdings, Inc....
BEDMINSTER, N.J., May 15, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that they have entered into a research collaboration with ViiV Healthcare, a global specialist HIV company established in November of 2009 by GlaxoSmithKline (LSE: GSK)...
Matinas BioPharma Holdings, Inc. Q1 2019 Earnings Conference Call May 14, 2019 8:30 AM Company Participants Jenene Thomas - IR Jerry Jabbour - Chief Executive Officer Conference Call Participants Robert Hazlett - BTIG Presentation Operator Greetings and welcome to ...
News, Short Squeeze, Breakout and More Instantly...
Matinas Biopharma Holdings Inc. Company Name:
MTNB Stock Symbol:
NYSE Market:
Matinas Biopharma Holdings Inc. Website:
BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces the recent successful...
BEDMINSTER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its ora...
BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data ...